VAQTA is indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older.
The primary dose should be given at least 2 weeks prior to expected exposure to HAV.
0843 504 8147
Get rapid results in 10 minutes with 5 simple steps. CE marked, these tests must be administered by a healthcare professional. Don't waste any time securing this rapid test product - they are going fast so hurry whilst stocks last!Buy Now